President and CEO
Delphi Scientific, LLC
Dr. Panagiotou the President and CEO of Delphi Scientific, LLC, a company that develops pharmaceurical nanoformulations and associate cGMP manufacturing technologies. She is recognized as an expert in nanomaterial processing, formulations and pertinent equipment design, and has served an Expert Witness in several patent litigations in this area, involving Big Pharma.
In her current role, Dr. Panagiotou collaborates with multiple pharmaceutical and biotech companies to develop and scale up novel nanoformulations, often with high complexity. Her work cuts across indications and drug delivery methods: vaccines, cancer, ocular, brain, antibiotics and anesthetics; small molecules, RNA/DNA and biologics; lipid, polymer and inorganic nanoparticles; injectables, inhalables, transdermals and orals. She works closely with CROs and CDMOs worldwide, including Europe, US and Canada, as well as with Instrumentation and Equipment manufacturers.
In the past, Dr. Panagiotou has served as the CTO of the Materials Processing Group of IDEX Corporation (Microfluidics, Quadro Engineering, Fitzpatrick and Matcon). In that position, Dr. Panagiotou was responsible for the overall direction of the technology, new product development and collaborations with Industry and Academia. She, also, held various management positions (CTO, VP/R&D, etc.) with Microfluidics International.
Dr. Panagiotou holds a MS and Ph.D. in Mechanical Engineering from Northeastern University. She co-authored over 70 papers for journals and conference proceedings, and is a co-inventor of several patents. For her development and commercialization work in microreaction technologies she was awarded with the NANO 50 International award.